文献速递乳腺癌妇科肿瘤支持与姑息治疗

年轻BRCA携带者乳腺癌后妊娠中辅助生殖技术的应用:一项国际队列研究

Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort study.
PubMed 文献 · Eur J Cancer · 2025-04-14

这项国际医院回顾性队列研究纳入2000至2020年间≤40岁确诊乳腺癌后妊娠的BRCA1/2携带者543例,其中436例自然受孕、107例采用辅助生殖技术(ART)受孕。中位随访5.2年,未观察到ART对无病生存期有明显不良影响(校正HR=0.72,95%CI 0.39-1.34)。

要点

  • 543例乳腺癌后妊娠的年轻BRCA1/2携带者中,436例自然受孕,107例使用ART受孕。
  • ART组与无ART组相比,受孕时年龄更大、激素受体阳性乳腺癌更常见、确诊至受孕中位时间更长。
  • 中位随访5.2年,ART对无病生存期未见明显不良影响(校正HR=0.72,95%CI 0.39-1.34)。

核心结论

  • 在乳腺癌后妊娠的年轻BRCA1/2携带者中,使用ART似乎与无病生存期事件风险增加无关(校正HR=0.72,95%CI 0.39-1.34)。

研究设计与样本

  • 国际、医院为基础的回顾性队列研究,纳入2000至2020年间≤40岁确诊乳腺癌后妊娠的BRCA1/2携带者。
  • 共543例BRCA1/2携带者,436例自然受孕,107例使用ART受孕。

主要发现

  • 107例ART妊娠中,45例(42.1%)使用诊断时冻存的卵母细胞/胚胎,33例(30.8%)在抗癌治疗后经控制性卵巢刺激行体外受精/卵胞浆内单精子注射或行排卵诱导后宫腔内人工授精或计划同房,21例(19.6%)经卵母细胞捐赠,8例(7.5%)ART类型缺失。
  • 与无ART组相比,ART组受孕时年龄更大、激素受体阳性乳腺癌更常见、从癌症确诊至受孕的中位时间更长。
  • 受孕后中位随访5.2年,未观察到ART对无病生存期的明显不良影响(校正HR=0.72,95%CI 0.39-1.34)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Very limited data exist on assisted reproductive technology (ART) use in BRCA1/2 carriers conceiving after breast cancer. This study aimed to investigate the safety of ART to achieve a pregnancy after breast cancer in BRCA1/2 carriers. METHODS: This is an international, hospital-based, retrospective cohort study including BRCA1/2 carriers with a pregnancy after prior breast cancer diagnosis at ≤ 40 years of age between 2000 and 2020. Outcomes were compared between young BRCA1/2 carriers who conceived using ART and those who conceived spontaneously. RESULTS: Among 543 BRCA1/2 carriers with a pregnancy after breast cancer, 436 conceived spontaneously and 107 using ART. Of 107 pregnancies achieved with ART, 45 (42.1 %) were obtained using oocytes/embryo cryopreserved at diagnosis, 33 (30.8 %) after controlled ovarian stimulation for in-vitro-fertilization/intracytoplasmic sperm injection or ovulation induction for intrauterine insemination or planned intercourse after anticancer treatments, 21 (19.6 %) after oocyte donation, while for 8 (7.5 %) patients type of ART was missing. Compared to patients in the no-ART group, those in the ART group were older at the time of conception, had more frequently hormone receptor-positive breast cancer and a longer median time from cancer diagnosis to conception. At a median follow-up of 5.2 years after conception, no apparent detrimental effect of ART on disease-free survival was observed (adjusted HR=0.72, 95 % CI 0.39-1.34). CONCLUSION: In young BRCA1/2 carriers with a pregnancy after breast cancer, ART use did not appear to be associated with increased risk of DFS events.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Magaton IM, Blondeaux E, Hamy AS, et al. Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort study. Eur J Cancer. 2025. PMID: 40300260. doi:10.1016/j.ejca.2025.115434

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。